Shots:
- Eli Lilly has reported P-IIIb (TOGETHER-PsA) trial assessing concomitant Taltz (ixekizumab) & Zepbound (tirzepatide) vs Taltz alone in 271 adults with active PsA & obesity or overweight with ≥1 weight-related condition
- Trial met its 1EP, with 31.7% of pts achieving ACR50 & ≥10% weight loss at Wk. 36 vs 0.8%, & met a key 2EP, showing a 64% relative increase in ACR50 (33.5% vs 20.4%); data to be presented in future & discussed with regulators
- Concomitant Taltz + Zepbound is also being evaluated in the ongoing TOGETHER-PsO trial against Taltz monotx. for treating adults who have mod. to sev. plaque psoriasis & obesity or overweight, with topline results expected in H1’26
Ref: Eli Lilly | Image: Eli Lilly | Press Release
Related News: InduPro Therapeutics Collaborates with Eli Lilly in ~$950M Oncology Therapeutic Discovery Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
